MorphoSys Announces Election of Two New Supervisory Board Members
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Election of Two New Supervisory Board Members
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Karin Eastham and Marc Cluzel Join MorphoSys's Supervisory Board
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that at
the Company's Annual Shareholder Meeting on Thursday, May 31, 2012, its
shareholders confirmed the appointment of Ms. Karin Eastham and Dr. Marc Cluzel
as new members of the Supervisory Board. Ms. Eastham and Dr. Cluzel replace
Prof. Dr. Jürgen Drews and Dr. Metin Colpan. Prof. Drews has been a member of
MorphoSys AG's Supervisory Board since 1998, while Dr. Colpan joined in 2004.
"We are pleased to announce the election of two experienced new members to our
Supervisory Board and look forward to working with them," commented Dr. Gerald
Möller, Chairman of the Supervisory Board of MorphoSys AG. "On behalf of the
Company, I would like to thank Professor Drews and Dr. Colpan for their
invaluable support in establishing MorphoSys as one of the world's leading
antibody companies."
The shareholders of MorphoSys AG approved the following substantive management
proposals put to vote at the meeting:
* Granting full discharge of the members of the Management and Supervisory
Boards in respect of their activities during the business year 2011.
* The re-appointment of Dr. Gerald Möller, Dr. Daniel Camus and Dr. Geoffrey
Vernon to the Company's Supervisory Board. Following the AGM, the members of
the Supervisory Board re-elected Dr. Möller as Chairman. Mr. Vernon was
elected Vice Chairman.
* The appointment of PricewaterhouseCoopers AG as auditors of the Company and
the MorphoSys Group for the business year 2012.
* The use of the net earnings of MorphoSys AG; Management and Supervisory
Boards recommended that the net profit of the business year 2011 is carried
forward as accumulated income.
At the Annual General Meeting 2012 of MorphoSys AG, 39.7% of the voting shares
were represented.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®) and
arYla(®) are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release:
http://hugin.info/130295/R/1616311/515446.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1616311]
Unternehmensinformation / Kurzprofil:
Datum: 31.05.2012 - 16:00 Uhr
Sprache: Deutsch
News-ID 151970
Anzahl Zeichen: 5317
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Election of Two New Supervisory Board Members"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
